This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ARHGEF17 / Rho guanine nucleotide exchange factor 17 · IHC design guide
Design Immunohistochemistry for ARHGEF17
Plan chromogenic ARHGEF17 IHC in paraffin sections with the catalog antibody starting at 2.5 μg/mL (datasheet: IHC-P). Expect cytoplasmic staining, including high staining in heart cardiomyocytes, and use controls because tissue staining reliability is uncertain (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ARHGEF17 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic staining in most tissues (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic in most tissues; high in cardiomyocytes (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Appendix+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep paraffin-section fixation consistent across samples. (standard IHC practice; not target-specific) | |
| Caveat | Tissue staining reliability is uncertain (HPA tissue IHC) | |
| Regulation | Regulation not reported (UniProt) | |
| Isoform / epitope | No listed isoforms; one 1–2063 chain (UniProt) |
Section 1
Recommended ARHGEF17 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is shown alongside published ARHGEF17 IHC methods for a ccRCC tissue array (PMC12008239) and colorectal tumor sections (PMC12775562).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A10510); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-ARHGEF17, 2.5 μg/mL (datasheet A10510) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ARHGEF17-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 at 95–98 °C for 20 min (page retrieval); consider EDTA pH 9.0 for colorectal FFPE sections (PMC12775562).
Section 2
What Is the Expected ARHGEF17 Staining Pattern?
Expect predominantly cytoplasmic ARHGEF17 staining in many tissues (HPA tissue IHC: cytoplasmic expression in most tissues), including cardiomyocytes, glial cells and cholangiocytes scored High (HPA tissue IHC). A membrane accent is plausible from ICC-IF, which reports additional plasma membrane localization (HPA subcellular). ARHGEF17 has no transmembrane segment (UniProt Q96PE2 topology). Treat tissue IHC calls cautiously: HPA rates their reliability Uncertain, pending external verification (HPA tissue IHC).
| Cytoplasmic staining in heart cardiomyocytes, with recognizable cell boundaries. | This matches a High cell-level IHC call (HPA: heart cardiomyocytes) and UniProt's report of high heart expression (UniProt Q96PE2 tissue specificity). Score the cardiomyocytes separately from surrounding cells; the HPA IHC profile remains Uncertain (HPA tissue IHC). |
| Predominantly nuclear staining, without a discernible cytoplasmic component. | This differs from the tissue IHC cytoplasmic profile and approved ICC-IF cytosolic location (HPA tissue IHC; HPA subcellular). Check controls and detection conditions before assigning it to ARHGEF17; the supplied sources do not establish a nuclear pattern. |
| Strong staining in cells reported as Not detected, such as bone marrow hematopoietic cells. | This conflicts with that cell-level observation (HPA: bone marrow hematopoietic cells, Not detected). Consider cross-reactivity or endogenous detection activity and compare a no-primary control (general IHC practice). A single discordant field cannot establish the cause. |
| Diffuse color across cells, stroma and blank spaces, with little cell-level definition. | This is difficult to reconcile with the reported cellular cytoplasmic pattern (HPA tissue IHC). Check a no-primary control, blocking, washes and detection exposure for nonspecific background (general IHC practice) before scoring tissue expression. |
| No staining in heart cardiomyocytes while the slide's counterstain and morphology are readable. | This misses a High reference pattern (HPA: heart cardiomyocytes; UniProt Q96PE2: high heart expression). Review the IHC-validated antibody's working conditions and a positive control (general IHC practice); HPA's Uncertain reliability prevents treating absence alone as proof of assay failure (HPA tissue IHC). |
💡Expected ARHGEF17 appearanceA persuasive positive shows cytoplasmic staining in High-scored cells such as heart cardiomyocytes (HPA tissue IHC), while nuclear-only staining or widespread cell-free color warrants a control check (HPA subcellular; general IHC practice).
| Cell and tissue choice | Heart cardiomyocytes, liver cholangiocytes and cerebral cortex glial cells are High examples (HPA tissue IHC). Appendix glandular cells and bone marrow hematopoietic cells are reported Not detected (HPA tissue IHC). These are cell-level comparisons, not guarantees for every specimen. |
| Compartment and topology | Tissue staining is described as cytoplasmic (HPA tissue IHC). ICC-IF places ARHGEF17 mainly in cytosol, additionally at plasma membrane (HPA subcellular); UniProt lists no transmembrane segment (UniProt Q96PE2 topology). Do not require a membrane rim in chromogenic IHC. |
| Antibody evidence | HPA007991 is IHC Uncertain but ICC Approved; HPA074658 has no IHC status listed and is ICC Approved (HPA antibodies). HPA describes medium agreement between tissue staining and RNA and pending external verification (HPA tissue IHC). Interpret an isolated IHC signal with controls. |
| Antigen retrieval | No ARHGEF17-specific retrieval response is established in the supplied UniProt or HPA records. Compare retrieval conditions using the same positive tissue and controls if optimizing an IHC-P assay (general IHC practice); do not infer a target-specific fixation effect. |
| IF/ICC Q: Should an IF image look identical to chromogenic tissue IHC? | A: Expect chiefly cytosolic signal with possible plasma membrane signal in ICC-IF (HPA subcellular: approved locations). Tissue IHC is summarized as cytoplasmic and its reliability is Uncertain (HPA tissue IHC); compare compartments without assuming identical visual intensity. |
| Situation | Likely cause | Next action |
|---|---|---|
| Heart cardiomyocytes lack signal. | The result disagrees with a High HPA cell-level call and UniProt heart expression (HPA tissue IHC; UniProt Q96PE2). The cause cannot be assigned from those records alone. | Check section integrity, primary antibody conditions, retrieval and detection with a positive control (general IHC practice). Record the absent result rather than overriding it with the reference call. |
| Color appears in the no-primary control. | Background can arise from the detection system or endogenous activity (general IHC practice); this control does not implicate ARHGEF17. | Assess the detection reagent and, for enzyme-based chromogenic detection, the appropriate endogenous-enzyme block; repeat with the same tissue and exposure conditions (general IHC practice). |
| Most compartments show a uniform haze. | Poorly resolved background obscures the reported cytoplasmic cell pattern (HPA tissue IHC); excess reagent or insufficient washing are general IHC possibilities. | Compare no-primary background, adjust antibody concentration and blocking, and wash consistently (general IHC practice). Score only cells with distinguishable staining. |
| A predominantly nuclear pattern persists. | It conflicts with HPA's cytoplasmic tissue profile and approved cytosolic ICC-IF assignment (HPA tissue IHC; HPA subcellular); its identity is unresolved. | Recheck focus, counterstain and no-primary control, then compare another independently validated reagent if available (general IHC practice). Report the compartment discrepancy. |
| Bone marrow hematopoietic cells stain as strongly as the chosen positive cells. | HPA reports those hematopoietic cells as Not detected (HPA tissue IHC). Cross-reactivity or endogenous detection activity is possible (general IHC practice). | Compare matched no-primary sections and cell-level morphology; inspect whether color follows the same compartments in each control (general IHC practice). Do not call the signal specific from intensity alone. |
| ICC-IF shows a membrane rim, but IHC-P shows mainly cytoplasm. | An additional plasma membrane location is approved for ICC-IF, whereas tissue IHC is summarized as cytoplasmic (HPA subcellular; HPA tissue IHC). | Score each application against its reported compartment pattern and its own controls (general IHC practice). Do not require a visible membrane rim to accept otherwise supported cytoplasmic IHC staining. |
Experiment evidence
IHC & IF images showing ARHGEF17 staining
A10510 · IHCImmunohistochemistry of TEM4 in human spleen tissue with TEM4 antibody at 2.5 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000110237-ARHGEF17/tissue/cerebral+cortex#imid_2791328
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000110237-ARHGEF17/tissue/colon#imid_2791246
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000110237-ARHGEF17/tissue/liver#imid_2791247
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000110237-ARHGEF17/tissue/kidney#imid_2791256
HPA · ICC-IF CACO-2Human Protein Atlas immunofluorescence, CACO-2, antibody HPA074658; green = ARHGEF17, blue = nucleus, red = microtubules.
HPA · ICC-IF CACO-2Human Protein Atlas immunofluorescence, CACO-2, antibody HPA074658; green = ARHGEF17, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ARHGEF17 IHC & IF
🧪Run adrenal gland first: glandular cells should stain (HPA: High in adrenal gland glandular cells). Run appendix glandular cells as the negative tissue (HPA: Not detected in appendix glandular cells); on the positive slide, use unstained cells outside the glandular compartment as an internal background comparison without assuming every such cell is target negative.
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Appendix (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ARHGEF17 in CACO-2, Rh30, SK-MEL-30, A-431, U-251MG, U2OS, with annotated localisation: Cytosol (approved) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) slide, a host-species-matched isotype control appropriate to the antibody’s monoclonal or polyclonal format, and a target knockout or immunogen-peptide-block control where available (standard IHC specificity controls). For chromogenic detection in adrenal gland, quench endogenous peroxidase and check background on the control slides (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported in the supplied evidence, and the fixative is unreported in the selected A10510 tissue-IHC caption (caption: fixative not stated). Retrieval dependence is also unreported; optimize antigen retrieval on paraffin sections before comparing staining (standard IHC practice). The supplied evidence does not establish whether frozen sections or IF are easier, or identify a tissue-specific artefact.
HPA tissue IHC evidence for ARHGEF17
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Caudate | Glial cells | High | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | High | Protein (IHC) | HPA → |
| Cerebral cortex | Glial cells | High | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Cervix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Rectum | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Salivary gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ARHGEF17 IHC Tips
Troubleshoot ARHGEF17 staining in chromogenic tissue IHC, with one section on adapting the experiment to IF.
How should I optimize retrieval when ARHGEF17 staining is weak?
Use citrate buffer at pH 6.0 for heat-induced retrieval at 95–98 °C for 20 min (page retrieval rule: cytoplasmic / membrane antigen). If signal remains weak, compare a longer citrate incubation with EDTA at pH 9 on adjacent sections, keeping the antibody and detection conditions constant (standard IHC optimization practice). Assess whether stronger staining preserves cell boundaries and tissue morphology, because excessive heating can make diffuse chromogen difficult to interpret (standard IHC practice). Judge improvement against cytoplasmic staining in cardiomyocytes or cholangiocytes, while treating those patterns as reference observations rather than proof of specificity (HPA tissue IHC: High in cardiomyocytes and cholangiocytes; reliability Uncertain).
Could fixation explain inconsistent ARHGEF17 staining between tissue blocks?
The selected ARHGEF17 tissue-IHC caption does not state a fixative, so target-specific fixation sensitivity is unknown (A10510 tissue-IHC caption: fixative not stated). Compare sections from blocks with documented fixation histories using the same pH 6.0, 20 min retrieval and identical staining runs (page retrieval rule; standard IHC practice). Record fixative, fixation duration, tissue thickness, and processing conditions before attributing a weak result to antigen abundance (standard IHC practice). Include a consistently processed reference section in each run, and assess morphology alongside signal to distinguish a block-wide processing problem from variation between cell populations (standard IHC practice).
What staining compartment should I expect for ARHGEF17?
Expect predominantly cytoplasmic chromogen in tissue sections, while allowing a membrane-associated component where cell outlines are resolvable (HPA tissue IHC: cytoplasmic expression in most tissues; HPA subcellular: cytosol and plasma membrane). ARHGEF17 has no annotated transmembrane segment, so a crisp membrane rim alone needs independent validation (UniProt Q96PE2 topology). Compare compartment patterns within the same section and against a positive reference, using identical counterstaining and exposure conditions when documenting images (standard IHC practice). Treat exclusively nuclear, luminal, or extracellular deposits as suspect until they persist with an independent antibody or another specificity control (HPA subcellular localisation; standard IHC practice).
How do epitope choice and modifications affect ARHGEF17 IHC?
Check where the antibody epitope lies relative to the DH domain at residues 1066–1254 and the recorded phosphorylation sites, including serines 142 and 152 (UniProt Q96PE2 domains and modified residues). No alternative isoforms are supplied in the record, so do not assign differing tissue patterns to specific isoforms without separate evidence (UniProt Q96PE2: isoforms 0). Compare retrieval conditions on adjacent sections if the epitope is known, because fixation and heat can change antibody access to an epitope (standard IHC practice). If staining changes after retrieval, confirm cell identity and compartment before interpreting the difference as altered ARHGEF17 abundance (HPA tissue IHC: reliability Uncertain; standard IHC practice).
How can I adapt the IHC observations to multiplex IF?
For multiplex IF, pair ARHGEF17 with a validated marker for the expected cell population, such as cardiomyocytes in heart muscle or glial cells in cerebral cortex (HPA tissue IHC: High in cardiomyocytes and cortical glial cells). Choose fluorophores after imaging an unstained section, assigning the weaker channel away from the tissue’s strongest autofluorescence (standard IF practice). Because the supported locations are cytosol and plasma membrane, test mild permeabilisation against an unpermeabilised condition according to whether the antibody epitope faces the cytosol or remains accessible from outside the cell (HPA subcellular localisation; standard IF practice). Validate the IF signal independently; the A10510 spleen caption documents tissue IHC, not IF performance (A10510 tissue-IHC caption).
What should I check when ARHGEF17 chromogen appears widespread?
Run a no-primary control and inspect unstained tissue for pigment or deposits before increasing the primary antibody concentration (standard IHC practice). For peroxidase detection, include an appropriate endogenous peroxidase block, optimize protein blocking and washes, and shorten chromogen development if background rises across the section (standard IHC practice). The selected A10510 image reports 2.5 µg/mL in human spleen tissue, but its caption does not establish that concentration as optimal for other tissues (A10510 tissue-IHC caption). Compare cellular staining with the negative control and morphology, particularly in spleen, where cells in red pulp were reported as not detected in a separate tissue survey (HPA tissue IHC: spleen red pulp Not detected).
How should I score ARHGEF17 staining across samples? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, since tissue IHC describes broad cytoplasmic expression while cell-type staining varies (HPA tissue IHC: cytoplasmic expression in most tissues; listed positive and negative populations). For comparable sections, report the percentage of positive cells and an H-score calculated from intensity categories, with the same thresholds applied to every slide (standard IHC quantification practice). If counting discrete positive cells, report density per mm² of viable tissue and exclude folds, edges, and necrosis by a documented rule (standard IHC practice). Normalize counts to the relevant cell population or viable tissue area, and include a common reference section to track variation between staining runs (standard IHC practice).
How do I distinguish genuine ARHGEF17 staining from artefact?
Favor reproducible cytoplasmic staining in anatomically identified cells, with possible plasma membrane signal, over staining confined to nuclei or extracellular material (HPA tissue IHC: cytoplasmic expression; HPA subcellular: cytosol and plasma membrane). Check whether staining follows section edges, folds, necrotic regions, or endogenous peroxidase activity in a no-primary control (standard IHC practice). Interpret the A10510 spleen image cautiously: its caption shows staining at 2.5 µg/mL, whereas a separate survey reports ARHGEF17 not detected in spleen red-pulp cells (A10510 tissue-IHC caption; HPA tissue IHC: spleen red pulp Not detected). Resolve that discrepancy by identifying the stained cells and seeking independent specificity evidence before calling them ARHGEF17-positive (HPA tissue IHC: reliability Uncertain; standard IHC practice).
Boster reagents
Best ARHGEF17 / Rho guanine nucleotide exchange factor 17 IHC Antibodies
A10510 is listed for human IHC-P and has a human spleen IHC image (catalog: applications, reactivity and image caption). No IF image is supplied (catalog: IF image list).
Real IHC data
Anti-TEM4 ARHGEF17 Antibody
Cat # A10510
A10510 is listed for human IHC-P (catalog: applications and reactivity). Its IHC image shows human spleen tissue at 2.5 μg/mL (catalog: IHC image caption).
Which to pick: Choose A10510 for human paraffin-section IHC; its application list includes IHC-P, and its image caption documents staining in human spleen tissue (catalog: applications and IHC image caption). For IF/ICC, A10510 has a suggested starting concentration of 20 μg/mL, but IF/ICC is absent from its application list and no IF image is supplied (catalog: dilution text, applications and IF image list). No cross-species option is listed because A10510 is the only supplied SKU and lists human reactivity; its IHC image caption does not report the fixative (catalog: reactivity and IHC image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q96PE2 (ARHGH_HUMAN, Rho guanine nucleotide exchange factor 17).
- Human Protein Atlas. ARHGEF17 tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. ARHGEF17 subcellular location (ICC-IF): Mainly localized to the cytosol. In addition localized to the plasma membrane..
- Human Protein Atlas. ARHGEF17 antibody validation summary (2 antibodies).
- Regulatory mechanism and prognostic value of sex hormone pathways connected with metabolism and immune signaling in clear cell renal cell carcinoma. Scientific reports 2025 — PMC12008239.
- A Robust Immunohistochemistry-Based Classification for BRAF V600E-Mutant Colorectal Cancer With Clinical Implications. Cancer science 2026 — PMC12775562.
- PubMed PMID:11559528 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ARHGEF17 (Rho guanine nucleotide exchange factor 17). Expected localisation Cytoplasmic staining in most tissues (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A10510 at 2.5 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Appendix. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A10510); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-ARHGEF17, 2.5 μg/mL (datasheet A10510); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep paraffin-section fixation consistent across samples. (standard IHC practice; not target-specific); Caveat: Tissue staining reliability is uncertain (HPA tissue IHC); Isoform / epitope: No listed isoforms; one 1–2063 chain (UniProt); Regulation: Regulation not reported (UniProt). Evidence: UniProt Q96PE2, HPA tissue IHC · Uncertain, HPA ICC-IF · Mainly localized to the cytosol. In addition localized to the plasma…, Datasheet A10510, PMC12008239, PMC12775562. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ARHGEF17/immunohistochemistry-ihc-guide.